A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy

Sponsor
Novo Nordisk A/S
Study ID
NCT04666987
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Insulin degludec and liraglutide (IDegLira) — DRUG
    Paricipants will be treated with commercially available Xultophy® according to routine clinical practice at the discretion of the treating physician, following approved label in Italy. The decision to initiate treatment with commercially available Xultophy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.

Study Details

The purpose of the study is to collect information on how Xultophy® works in patients like them with type 2 diabetes. Participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 18 months. Participants will be asked questions about their health and diabetes treatment as part of the normal study doctor's appointment.

Key Dates

Start date
Oct 21, 2020
Status verified
Apr 2024
Primary completion
Dec 30, 2022
Completion
Feb 10, 2023

Study Design

Enrollment
359 participants (actual)

Arms

  • Arm: Xultophy®
    Participants are patients with Type 2 Diabetes (T2D) treated with Xultophy® (IDegLira) in a real-world setting in Italy

Primary Outcome Measure

Change in Glycated Haemoglobin (HbA1c) [ Time Frame: From baseline (V0, month 0) to 6 months after initiation. ]

Related Studies